Generic Name and Formulations:
Prednisone 1mg, 2mg, 5mg; delayed-release tablets.
Indications for RAYOS:
Adults and Children:
See full labeling. Swallow whole with food. Individualize. The timing of administration should take into account the delayed-release pharmacokinetics (approximately 4-hour lag time from that of immediate-release prednisone) and the disease or condition being treated. Use lowest effective dose. Initially 5–60mg day. Conversion from immediate-release prednisone, prednisolone, or methylprednisolone: give equivalent dose based on relative potency.
For prednisone in general: Systemic fungal infections, cerebral malaria, optic neuritis: not recommended. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. May increase risk and mask signs of infection. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. HPA axis suppression. Cushing’s syndrome. Hyperglycemia. Thyroid disorders. Hypertension. CHF. Renal insufficiency. Recent MI. Risk of GI perforation. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Kaposi’s sarcoma. May cause electrolyte imbalances or psychotic manifestations. Avoid abrupt cessation. Monitor weight, growth, BP, IOP, fluid and electrolyte balance. Elderly. Pregnancy (Cat.D). Nursing mothers.
See Contraindications. Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine, aminoglutethimide. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin or NSAIDs. Caution with aspirin in hypoprothrombinemia. Monitor for hypokalemia with potassium-depleting drugs. Withdraw anticholinesterase agents at least 24hrs before initiating therapy. May suppress reactions to skin tests.
Fluid retention, alteration in glucose tolerance, BP elevation, behavioral/mood changes, increased appetite, weight gain.
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd